Article Data

  • Views 246
  • Dowloads 142

Original Research

Open Access

Nomogram for the prediction of disease-free survival in FIGO 2023 stage IA2 endometrial cancer patients

  • Aykut Özcan1
  • Varol Gülseren2,*,
  • İlker Çakır1
  • Mehmet Özer1
  • Muzaffer Sancı1
  • Kemal Güngördük3

1Department of Obstetrics and Gynecology, Tepecik Education and Research Hospital, 35020 İzmir, Turkey

2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Erciyes University, 38039 Kayseri, Turkey

3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Muğla Sıtkı Koçman University, 48000 Muğla, Turkey

DOI: 10.22514/ejgo.2024.087

Submitted: 24 June 2024 Accepted: 07 August 2024

Online publish date: 26 September 2024

*Corresponding Author(s): Varol Gülseren E-mail: varol.gul@erciyes.edu.tr

Abstract

The purpose of the research is to assess the risk factors that contribute to the recurrence of International Federation of Gynecology and Obstetrics (FIGO) 2023 stage IA2 endometrial cancer (EC) patients. The study was conducted by examining stage IA2 patients who underwent surgery for EC in the gynecological oncology clinic between 2008–2022. Study data were collected by retrospective evaluation. A total of 185 patients, 37 with recurrence and 148 in the control group, were included in the study. In the study, the recurrence rate among all stage IA2 EC was found to be 3.9%. The mean age was similar between the groups. Grade 2 tumors were found in 73.0% of patients in the case group and 34.5% in the control group. Tumor size was larger in the case group. Neutrophil lymphocyte ratio (NLR) value was significantly higher in the case group. Adjuvant radiotherapy was given to 42.6% of patients in the control group and 59.5% in the case group. The nomogram’s score was assessed for disease-free survival (DFS) using Concordance Correlation Coefficient analysis. The Concordance index (C-index) for the nomogram was 0.903. When 5-year DFS times were analyzed according to total nomogram score, a significant difference was found. Grade 2 tumor classification, negative estrogen receptor status, elevated cancer antigen 125 (CA125) levels (>35), large tumor size (≥3.0 cm) and high NLR (≥1.9) are identified as significant risk factors for recurrence in early-stage (IA2) and low-Grade EC patients. The total score derived from the nomogram constructed with these risk factors shows a notable variation in DFS.


Keywords

Endometrial cancer; Disease-free survival; Recurrence; Neutrophil lymphocyte ratio


Cite and Share

Aykut Özcan,Varol Gülseren,İlker Çakır,Mehmet Özer,Muzaffer Sancı,Kemal Güngördük. Nomogram for the prediction of disease-free survival in FIGO 2023 stage IA2 endometrial cancer patients. European Journal of Gynaecological Oncology. 2024.doi:10.22514/ejgo.2024.087.

References

[1] Alhadeethi A, Ibrahim AA, Atia A, Alabdallat YJ, Alkhawaldeh IM, El Din Moawad MH. Clinical characteristics and prognostic factors of endometrial cancer patients with liver metastasis: a surveillance, epidemiology, and end results database (SEER)-based study of 1,034 women. Cureus. 2024; 16: e54606.

[2] Zheng Y, Jiang P, Tu Y, Huang Y, Wang J, Gou S, et al. Incidence, risk factors, and a prognostic nomogram for distant metastasis in endometrial cancer: a SEER-based study. International Journal of Gynaecology and Obstetrics. 2024; 165: 655–665.

[3] Xue Q, Che W, Xue L, Zhang X, Wang X, Lyu J. Causes of death in endometrial cancer survivors: a surveillance, epidemiology, and end result-based analysis. Cancer Medicine. 2023; 12: 10917–10930.

[4] Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al.; Endometrial Cancer Staging Subcommittee, FIGO Women’s Cancer Committee. FIGO staging of endometrial cancer: 2023. International Journal of Gynaecology and Obstetrics. 2023; 162: 383–394.

[5] Markowska A, Baranowski W, Pityński K, Chudecka-Głaz A, Markowska J, Sawicki W. Metastases and recurrence risk factors in endometrial cancer-the role of selected molecular changes, hormonal factors, diagnostic methods and surgery procedures. Cancers. 2023; 16: 179.

[6] Kaewpangchan P, Cheewakriangkrai C. Relapse patterns and outcomes following recurrence of endometrial cancer in Northern Thai women. Asian Pacific Journal of Cancer Prevention. 2015; 16: 3861–3866.

[7] Jeppesen MM, Jensen PT, Gilså Hansen D, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence—a national cohort study. European Journal of Cancer. 2016; 69: 51–60.

[8] Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[9] Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T; Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecologic Oncology. 2006; 101: 520–529.

[10] Francis SR, Ager BJ, Do OA, Huang YJ, Soisson AP, Dodson MK, et al. Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy. Gynecologic Oncology. 2019; 154: 38–44.

[11] Rios-Doria E, Cun HT, Filippova OT, Mueller JJ, Alektiar KM, Ellenson LH, et al. Isolated vaginal recurrence in women with stage I endometrial cancer. Gynecologic Oncology. 2023; 179: 9–15.

[12] Parsons MW, Huang YJ, Burt L, Suneja G, Gaffney D. Vaginal cuff brachytherapy for endometrial cancer: a review of major clinical trials with a focus on fractionation. International Journal of Gynecological Cancer. 2022; 32: 311–315.

[13] Laban M, El-Swaify ST, Ali SH, Refaat MA, Sabbour M, Farrag N, et al. The prediction of recurrence in low-risk endometrial cancer: is it time for a paradigm shift in adjuvant therapy? Reproductive Sciences. 2022; 29: 1068–1085.

[14] Krusun S, Pesee M, Rasio W, Tangvoraphonkchai V, Supaadirek C, Thamronganantasakul K, et al. Survival rate of early stage endometrioid adenocarcinoma of endometrium treated at Srinagarind Hospital. Asian Pacific Journal of Cancer Prevention. 2014; 15: 2217–2220.

[15] Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al; PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecologic Oncology. 2003; 89: 201–209.

[16] Kim SR, Pina A, Albert A, McAlpine JN, Wolber R, Gilks B, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. International Journal of Gynecological Cancer. 2020; 30: 783–788.

[17] Güngördük K, Firat Cüylan Z, Kahramanoglu I, Oge T, Akbayir O, Dede M, et al. Risk factors for recurrence in low-risk endometrial cancer: a case-control study. Oncology Research and Treatment. 2018; 41: 466–470.

[18] Nahshon C, Kadan Y, Lavie O, Ostrovsky L, Segev Y. Sentinel lymph node sampling versus full lymphadenectomy in endometrial cancer: a SEER database analysis. International Journal of Gynecological Cancer. 2023; 33: 1557–1563.

[19] Bogani G, Giannini A, Vizza E, Di Donato V, Raspagliesi F. Sentinel node mapping in endometrial cancer. Journal of Gynecologic Oncology. 2024; 35: e29.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top